In 198 people aged ≥60 with geographic atrophy, oral gildeuretinol acetate did not significantly slow 24-month lesion growth vs placebo (1.62 vs 1.87 mm²/yr; P=0.075). Exploratory visual function outcomes favoured gildeuretinol (nominal P values only).
RCTn = 198
Boyer et al. Gildeuretinol Acetate versus Placebo for Geographic Atrophy Secondary to Age-Related Macular Degeneration: The Study of ALK-001 in Geographic Atrophy Randomized Clinical Trial